ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help

Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

Social Anxiety Disorder Linked to High Serotonin Levels, Throwing Treatment with SSRIs into Serious ...

A short-term Borrelia burgdorferi infection model identifies tissue tropisms and bloodstream surviva...

Can Botanicals Beat Brain Fog & Fibrofog?

Therapeutic Effects and Mechanisms of Action of Rifaximin in Gastrointestinal Diseases

Immune response to a flu vaccine yields new insights into narcolepsy

Children with Lyme Disease

Omega-3 supplements and antioxidants may help with preclinical Alzheimer's disease

Promoting Optimal Nutrition with Digestive Enzymes

7-Keto DHEA The Fat-Burning Metabolite of DHEA

Health Benefits of Ginseng

 
Print Page
Email Article

FDA Approves Pfizer Antifungal Medicine Vfend(R) (voriconazole)

  [ 119 votes ]   [ Discuss This Article ]
www.ProHealth.com • May 29, 2002





New drug expands options for treatment of life-threatening fungal infections

NEW YORK, May 28 /PRNewswire-FirstCall/ -- Pfizer Inc said today that the
U.S. Food and Drug Administration has given marketing clearance for both oral
and intravenous formulations of Vfend(R) (voriconazole) for the treatment of
deadly fungal infections.

Vfend is indicated for primary treatment of acute invasive aspergillosis
and salvage therapy for rare but serious fungal infections caused by the
pathogens Scedosporium apiospermum and Fusarium spp. In the largest clinical
trial of its kind, Vfend demonstrated superior efficacy and a survival benefit
versus the current treatment standard, amphotericin B, for primary treatment
of invasive aspergillosis, a deadly fungal infection occurring in immune
compromised patients.

The number of patients at risk for serious fungal infections is growing as
more patients undergo bone marrow and solid organ transplants as well as
aggressive chemotherapy for cancer. Fungal infections in these immunosuppressed patients are associated with high morbidity and mortality and
require prompt and effective treatment.

Vfend was discovered by Pfizer researchers in Sandwich, England and was
developed to address the unmet medical need for more effective and
better-tolerated options for patients with invasive aspergillosis and other
serious fungal infections.

Results from the largest prospective comparative clinical trial in
invasive aspergillosis ever conducted showed that 53 percent of patients who
received Vfend had a successful response at 12 weeks of treatment, compared to
32 percent of those who received amphotericin B. The survival rate of the
Vfend-treated patients was 71 percent versus 58 percent of those in the
amphotericin B arm of the study.

Vfend can be administered both orally and intravenously, unlike most
current available treatments. This allows for flexibility in patient care
with Vfend, permitting step-down therapy, an important consideration when
treating invasive fungal infections.

The most common side effects reported among Vfend patients were visual
disturbances, elevations of liver function tests and skin rash. These were
generally mild to moderate in severity and usually did not result in
discontinuation of treatment.

Pfizer said Vfend will be available in hospitals this summer.

Pfizer Inc discovers, develops, manufactures and markets leading
prescription medicines, for humans and animals, and many of the world's
best-known consumer products.

Full prescribing information is available upon request, or at
http://www.pfizer.com.



Please Discuss This Article:   Post a Comment 



[ Be the first to comment on this article ]




 
Free Chronic Fatigue Syndrome and Fibromyalgia Newsletters
Subscribe to
Our FREE
Newsletter
Subscribe Now!
Receive up-to-date ME/CFS & Fibromyalgia treatment and research news
 Privacy Guaranteed  |  View Archives

Save on Nutritional Supplement Orders

Featured Products

Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
Vitamin D3 Extreme™ Vitamin D3 Extreme™
50,000 IU Vitamin D3 - Prescription Strength
Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health
FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid

Natural Remedies

Undenatured Type II Collagen - Chicken Soup for Your Joints Undenatured Type II Collagen - Chicken Soup for Your Joints
Nutrients to Combat the Modern Stress Epidemic Nutrients to Combat the Modern Stress Epidemic
The Remarkable Benefits of Reishi Medicinal Mushrooms The Remarkable Benefits of Reishi Medicinal Mushrooms
Vitamin E: Super Antioxidant We Only Thought We Knew Vitamin E: Super Antioxidant We Only Thought We Knew
Ubiquinol - A More Advanced Form of the Energy Producing Nutrient CoQ-10 Ubiquinol - A More Advanced Form of the Energy Producing Nutrient CoQ-10

FIBROMYALGIA RESOURCES
What is Fibromyalgia?
Fibromyalgia Diagnosis
Fibromyalgia Symptoms
Fibromyalgia Treatments
| CFS RESOURCES
What is CFS?
ME/CFS Diagnosis
ME/CFS Symptoms
ME/CFS Treatments
| FORUMS
Fibromyalgia
ME/CFS
ADVANCED MEDICAL LABS
WHOLESALE  |  AFFILIATES
GUARANTEE  |  PRIVACY
CONTACT US
LIBRARY
RSS
SITE MAP
ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus
Credit Card Processing